Drug Profile
Umibecestat - Amgen
Alternative Names: AMG 520; CNP-250; CNP520Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Amgen; Novartis
- Class Antidementias; Oxazines; Pyridines; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Alzheimer's disease
Most Recent Events
- 05 Aug 2021 Novartis and Amgen terminates the phase II/III GS2 trial in Alzheimer's disease in USA, Argentina, Australia, Belgium, Canada, Chile China, Finland, France, Germany, Iceland, Israel, Italy, Japan, Mexico, Netherlands, Portugal, Puerto Rico, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan and United Kingdom due to safety issues (NCT03131453)
- 09 Aug 2019 Chemical structure information added
- 15 Jul 2019 Discontinued - Phase-II/III for Alzheimer's disease in Argentina, Australia, Netherlands, United Kingdom, Germany, Taiwan, South Korea, South Africa, Portugal, Portugal, Singapore, Mexico, Japan, Italy, Israel, Iceland, France, China, Chile, Canada (PO)